- Home
- ZDGE vs RFL Comparison
ZDGE vs RFL Comparison
Compare ZDGE & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDGE
- RFL
- Stock Information
- Founded
- ZDGE 2008
- RFL 2017
- Country
- ZDGE United States
- RFL United States
- Employees
- ZDGE N/A
- RFL N/A
- Industry
- ZDGE Computer Software: Prepackaged Software
- RFL Real Estate
- Sector
- ZDGE Technology
- RFL Finance
- Exchange
- ZDGE Nasdaq
- RFL Nasdaq
- Market Cap
- ZDGE 51.8M
- RFL 48.4M
- IPO Year
- ZDGE N/A
- RFL N/A
- Fundamental
- Price
- ZDGE $3.61
- RFL $2.03
- Analyst Decision
- ZDGE
- RFL
- Analyst Count
- ZDGE 0
- RFL 0
- Target Price
- ZDGE N/A
- RFL N/A
- AVG Volume (30 Days)
- ZDGE 47.6K
- RFL 47.3K
- Earning Date
- ZDGE 10-24-2024
- RFL 10-28-2024
- Dividend Yield
- ZDGE N/A
- RFL N/A
- EPS Growth
- ZDGE N/A
- RFL N/A
- EPS
- ZDGE N/A
- RFL N/A
- Revenue
- ZDGE $29,142,000.00
- RFL $540,000.00
- Revenue This Year
- ZDGE $13.67
- RFL N/A
- Revenue Next Year
- ZDGE $13.41
- RFL N/A
- P/E Ratio
- ZDGE N/A
- RFL N/A
- Revenue Growth
- ZDGE 4.15
- RFL 92.86
- 52 Week Low
- ZDGE $1.70
- RFL $1.29
- 52 Week High
- ZDGE $5.18
- RFL $2.14
- Technical
- Relative Strength Index (RSI)
- ZDGE 58.17
- RFL 76.12
- Support Level
- ZDGE $3.55
- RFL $1.65
- Resistance Level
- ZDGE $3.75
- RFL $1.94
- Average True Range (ATR)
- ZDGE 0.20
- RFL 0.10
- MACD
- ZDGE 0.05
- RFL 0.01
- Stochastic Oscillator
- ZDGE 80.07
- RFL 100.00
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.